Online citations, reference lists, and bibliographies.
← Back to Search

The Dystonias.

C. Marsden, N. Quinn
Published 1990 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
or referring general practitioner. The problem is that other aspects of the university hospital's work previously funded in a general way out of SIFT would then be left unfunded unless additional resources were found. What structure of funding would help to guarantee the future ofmedical education, research, and development in the NHS? How can we be sure to continue to attract many of the best brains into health care and use them to the full? Can we deny that while university hospitals surely must submit to strict managerial, medical, and educational audit (much of which they have themselves devised) their true success will never be measurable in commercial terms, that medical knowledge and development will be constrained in a market where cost effectiveness is the touchstone? Are we really prepared to see medical education and science jeopardised by the uncertain outcome of a market environment aimed at solving completely different problems? There is no reason to doubt the sincerity and truth of Mr Clarke's statement on 10 July 1989 that "The comprehensive and high quality health service which will be needed to face the demands and challenges of tomorrow's world will depend crucially on the standard of medical education we provide and the range and quality of the nation's medical research programmes. Both are an intrinsic part of our commitment to the NHS" (speech to doctors in London). We believe that the solution is to accept that it is in the national interest to have a small number of institutions whose special task it is to set the highest standards of care, to advance knowledge, and to inspire future doctors to excellence in a rapidly changing world, sending them out to every part of Britain once qualified with these models of care before them; and further, to accept that excellence is costly and must be funded, managed, and assessed in its own right but is at the same time a key componQnt of care in the inner cities. This requires direct funding of the main university teaching hospitals by the Department of Health with a managerial mandate similar to that of the existing special health authorities but with the crucial difference that the undergraduate teaching hospitals continue to serve their locality as well as the country at large. Direct funding will not solve all the problems but it will greatly simplify the administrative process, stabilise the financial base, and allow time, energy, and imagination to be concentrated on the fundamental educational challenge, which has long been submerged in other pressures.
This paper references
Dopa-responsive dvstonia
F G Nygaard (1988)
10.1093/BRAIN/108.3.593
Pathophysiology of blepharospasm and oromandibular dystonia.
A. Berardelli (1985)
A genetic stttdy otf idiopathic torsion dystonia in the UK
N A Fletcher
10.1001/ARCHNEURPSYC.1944.02290280003001
DYSTONIA: I. HISTORICAL REVIEW; ANALYSIS OF DYSTONIC SYMPTOMS AND PHYSIOLOGIC MECHANISMS INVOLVED
E. Herz (1944)
10.1093/BRAIN/112.3.681
Reciprocal inhibition between forearm muscles in patients with writer's cramp and other occupational cramps, symptomatic hemidystonia and hemiparesis due to stroke.
K. Nakashima (1989)
10.1093/BRAIN/108.2.463
The anatomical basis of symptomatic hemidystonia.
C. Marsden (1985)
10.1056/NEJM198608073150602
Brain neurotransmitters in dystonia musculorum deformans.
O. Hornykiewicz (1986)
Botulinum toxin in spasmodic torticollis.
J. Tsui (1988)
10.1136/jnnp.52.3.355
Treatment of focal dystonias of the hand with botulinum toxin injections.
L. Cohen (1989)
Inheritance of idiopathic torsion dystonia among Ashkenazi Jews.
S. Bressman (1988)
10.1212/WNL.39.10.1354
An exteroceptive reflex in the sternocleidomastoid muscle produced by electrical stimulation of the supraorbital nerve in normal subjects and patients with spasmodic torticollis
K. Nakashima (1989)
Classification and investigation of dystonia
S Fahn (1987)
Multiple sclerosis in Rochester, Minnesota--a 60-year appraisal.
A. Percy (1968)
Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion.
N. Quinn (1988)
Epidemiology of focal and generalised dvstonia in
J G Nutt (1988)
Uber eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (dysbasia lordotica progressisa, dystonia musculorum deformans)
H Oppenheim (1911)
10.1136/jmg.21.1.13
Inheritance of idiopathic torsion dystonia among Jews.
N. Zilber (1984)
10.1212/WNL.38.5.702
Pathology in brainstem regions of individuals with primary dystonia
R. Zweig (1988)
10.1136/jnnp.51.6.767
Blepharospasm: a review of 264 patients.
F. Grandas (1988)
Investigation of dystonia.
C. Marsden (1988)
Genetics and epidemiology of Parkinson's disease
F T Nobrega (1967)
10.1212/WNL.38.8.1220
Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia
C. Ludlow (1988)
10.1016/0896-6273(89)90188-8
Human gene for torsion dystonia located on chromosome 9q32-q34
L. Ozelius (1989)
10.1002/ANA.410020405
Familial paroxysmal dystonic choreoathetosis and its differentiation from related syndromes
J. Lance (1977)



This paper is referenced by
10.1017/S0022215100122650
The use of clostridium botulinum toxin in palatal myoclonus. A preliminary report.
S. Saeed (1993)
10.1007/BF02193087
Tardive Dystonia
M. Raja (2005)
10.1136/jmg.35.10.878-a
High frequency of the haemochromatosis C282Y mutation in Hungary could argue against a Celtic origin of the mutation.
A. Tordai (1998)
10.1111/j.1365-2990.2005.00703.x
Age‐related changes in striatal nitric oxide synthase‐immunoreactive interneurones in the dystonic dt sz mutant hamster
S. E. Sander (2006)
10.1007/BF01997715
Tardive dystonia
M. Raja (2005)
10.1111/j.1468-1331.2004.00845.x
Efficacy of pharmacological treatment of dystonia: evidence‐based review including meta‐analysis of the effect of botulinum toxin and other cure options
Y. Balash (2004)
10.1097/01.pra.0000388631.67275.16
A Biopsychosocial Approach to Improving Quality of Life in Tardive Dystonia
Charlotte Buscombe (2010)
10.1038/sj.bjp.0704268
Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia
A. Richter (2001)
10.1111/j.1600-0404.1999.tb07356.x
Phenotypic variability of the DYT1 mutation in German dystonia patients
B. Leube (1999)
10.1212/WNL.40.9.1458
Progressive dystonia following resuscitation from cardiac arrest
K. Boylan (1990)
10.1111/j.1651-2227.1996.tb14109.x
Intrathecal baclofen for severe torsion dystonia in a child
G. Paret (1996)
10.1177/197140099500800104
La risonanza magnetica nello studio del sistema extrapiramidale
M. Resta (1995)
10.1136/jnnp.56.5.526
The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
R. Whurr (1993)
PAROXYSMAL KINESIOGENIC CHOREOATHETOSIS: A FREQUENTLY MISDIAGNOSED MOVEMENT DISORDER
R. Garg (1993)
10.1111/j.1750-3639.1992.tb00707.x
The Autosomal Dominant Dystonias
T. Gasser (1992)
10.3389/fncir.2013.00156
IP3R1 deficiency in the cerebellum/brainstem causes basal ganglia-independent dystonia by triggering tonic Purkinje cell firings in mice
C. Hisatsune (2013)
10.1017/S0317167100038233
Relationship between sleep, neck muscle activity, and pain in cervical dystonia.
F. Lobbezoo (1996)
Mitochondrial dysfunction in the pathogenesis of neurodegeneration.
S. Tabrizi (2000)
10.1177/026921639500900104
Medical and nursing problems of children with neurodegenerative disease
Anne Hunt Helen (1995)
10.1136/jmg.38.1.43
Sensitivity and predictive value of criteria for p53germline mutation screening
A. Chompret (2001)
10.2165/00019053-199712060-00009
Costs of Treating Dystonias and Hemifacial Spasm with Botulinum Toxin A
R. Dodel (2012)
10.1136/jnnp.64.4.427
The molecular genetics of the dystonias
T. Warner (1998)
10.1016/j.expneurol.2012.11.019
Neuropathology of cervical dystonia
C. Prudente (2013)
10.7916/D85X27N2
“Club-Cutting” Dystonic Tremor: a Case Report
K. Roberts (2013)
10.1136/bmj.300.6723.536-d
The dystonias.
Charles H. Markham (1992)
10.7916/D8959HR1
Overuse Cervical Dystonia: A Case Report and Literature Review
Elliot Hogg (2016)
10.1006/DBIO.1997.8567
Developmental expression of BPAG1-n: insights into the spastic ataxia and gross neurologic degeneration in dystonia musculorum mice.
J. Dowling (1997)
10.1038/SJ.BDJ.4801587
Recurrent dislocation of the temporomandibular joints: a diagnostic and treatment problem
G. Wood (2002)
Diagnóstico y tratamiento de la distonía aguda
F. Escobar (2005)
10.1016/0304-3959(96)03153-3
Pain perception in idiopathic cervical dystonia (spasmodic torticollis)
F. Lobbezoo (1996)
10.1016/0304-3959(94)90048-5
Botulinum toxin in the treatment of myofascial pain syndrome
W. Cheshire (1994)
10.1111/j.1469-8749.2004.tb01026.x
Congenital suprabulbar palsy: a distinct clinical syndrome of heterogeneous aetiology
Poovathinal A Suresh (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar